8.34
0.04 (0.48%)
| Previous Close | 8.30 |
| Open | 8.35 |
| Volume | 31,259 |
| Avg. Volume (3M) | 93,925 |
| Market Cap | 757,495,296 |
| Price / Earnings (TTM) | 417.00 |
| Price / Earnings (Forward) | 188.68 |
| Price / Sales | 7.51 |
| Price / Book | 7.42 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | 7.20% |
| Operating Margin (TTM) | 10.31% |
| Diluted EPS (TTM) | 0.020 |
| Quarterly Revenue Growth (YOY) | -18.80% |
| Quarterly Earnings Growth (YOY) | -64.20% |
| Total Debt/Equity (MRQ) | 1.52% |
| Current Ratio (MRQ) | 3.60 |
| Operating Cash Flow (TTM) | -6.65 M |
| Levered Free Cash Flow (TTM) | -8.55 M |
| Return on Assets (TTM) | 5.18% |
| Return on Equity (TTM) | 12.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Gyre Therapeutics, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 91.25% |
| % Held by Institutions | 2.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| State Of Wisconsin Investment Board | 30 Jun 2025 | 37,670 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (HC Wainwright & Co., 115.83%) | Buy |
| Median | 17.00 (103.84%) | |
| Low | 16.00 (Jefferies, 91.85%) | Buy |
| Average | 17.00 (103.84%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 10 Oct 2025 | 16.00 (91.85%) | Buy | 7.96 |
| HC Wainwright & Co. | 26 Aug 2025 | 18.00 (115.83%) | Buy | 7.76 |
No data within this time range.
| 3Y Average Dividend Yield | 6.31% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 Cash |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 Cash |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.93 |
| 2022 | 1.43 | 1 | 17.99 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |